cis-(2S,4S) 4-amino-proline (cAmp) and trans-(2S,4R) 4-amino-proline (tAmp) residues, bearing N-For or N-Boc substituents at the two amino groups, have been incorporated into the potent chemotactic agent fMLF-OMe in place of the N-terminal native (S)-methionine to give the analogues 17a-19a and 17b-19b. The new ligands have been examined for their activity (chemotaxis, superoxide anion production and lysozyme release) on human neutrophils as agonists and antagonists. Compounds 19a and 19b, bearing two N-For groups at the proline scaffold, are active and selective chemoattractants. The ligand 18b, containing N-For at the 4-amino group of the N-Boc-tAmp residue, exhibits significant chemotactic antagonism. The influence of the different substitution at the N-terminal position of the new analogues is discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmc.2008.11.010 | DOI Listing |
BMC Musculoskelet Disord
October 2024
Institute for Biomechanics, BG Unfallklinik Murnau Professor Küntscher Str. 8, 82418, Murnau, Germany.
Introduction: Proximal humerus fractures are usually treated with rigid angle-stable plates or nails. As an alternative, semi-rigid, minimally invasive systems have been developed for supportive fixation. A new system uses this principle with 2.
View Article and Find Full Text PDFClin Biomech (Bristol)
December 2024
Musculoskeletal Translational Innovation Initiative, Carl J. Shapiro Department of Orthopaedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Mechanical Engineering Department, Boston University, Boston, USA; Department of Orthopedic Surgery, Yerevan State Medical University, Yerevan, Armenia. Electronic address:
Background: Stemless shoulder arthroplasty offers several advantages, such as preserving bone stock and reducing periprosthetic fracture risk. However, implant motion can deter osteointegration and increase bone resorption, where micromotion less than 0.150 mm is crucial for bony ingrowth and vital to the success of the implant.
View Article and Find Full Text PDFNeurology
September 2024
From the Albert Einstein College of Medicine (R.B.L.), Bronx, NY; Massachusetts General Hospital (A.M.H.), Boston; AbbVie (J.Y.M., J.S., P.G., J.M.T.), Madison, NJ; AbbVie (J.H.S., K.J.-P., G.S.J.), North Chicago, IL; Department of Neurology (D.W.D.), Mayo Clinic, Scottsdale, AZ; and Atria Academy of Science and Medicine (D.W.D.), New York, NY.
Background And Objectives: Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The PRODROME trial previously demonstrated that ubrogepant treatment during prodrome prevents the onset of moderate or severe headache. In this analysis of the PRODROME trial, the benefits of ubrogepant treatment during the prodrome on patient-reported outcomes (PROs) are evaluated.
View Article and Find Full Text PDFClin Orthop Surg
August 2024
Orthopaedic Biomechanics Laboratory, Congress Medical Foundation, Pasadena, CA, USA.
J Mech Behav Biomed Mater
September 2024
University of Waterloo, Department of Kinesiology and Health Sciences, Waterloo, ON, Canada. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!